Replies to post #177299 on Biotech Values

[DewDiligence]

It will take 20 years to treat all HCV patients, according to Jay Luly (CEO of ENTA) on today's DB webcast.

[DewDiligence]

ABBV raises 2014 EPS guidance by $0.06:

http://finance.yahoo.com/news/not-release-publication-distribution-whole-114500528.html

AbbVie today raised the midpoint of its full-year 2014 earnings-per-share guidance by six cents and now expects a full-year diluted earnings-per-share range of $3.06 to $3.16 on an adjusted [i.e. non-GAAP] basis, or $2.69 to $2.79 on a GAAP basis.

This increase in guidance has nothing to do with the expected US launch of ABBV/ENTA’s 3-DAA HCV regimen in late 2014; earnings from the HCV launch have explicitly been excluded from the EPS guidance ranges due to the uncertainty with respect to launch timing.